Biogen Price to Book Ratio 2010-2022 | BIIB

Historical price to book ratio values for Biogen (BIIB) over the last 10 years. The current price to book ratio for Biogen as of July 01, 2022 is 2.76.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Biogen Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2022-07-01 210.63 2.77
2022-03-31 210.60 $76.07 2.77
2021-12-31 239.92 $74.56 3.22
2021-09-30 282.99 $74.08 3.82
2021-06-30 346.27 $75.22 4.60
2021-03-31 279.75 $70.80 3.95
2020-12-31 244.86 $70.12 3.49
2020-09-30 283.68 $69.81 4.06
2020-06-30 267.55 $71.32 3.75
2020-03-31 316.38 $74.71 4.23
2019-12-31 296.73 $87.53 3.39
2019-09-30 232.82 $76.92 3.03
2019-06-30 233.87 $70.20 3.33
2019-03-31 236.38 $71.29 3.32
2018-12-31 300.92 $66.08 4.55
2018-09-30 353.31 $68.29 5.17
2018-06-30 290.24 $60.83 4.77
2018-03-31 273.82 $66.53 4.12
2017-12-31 318.57 $59.57 5.35
2017-09-30 313.12 $60.76 5.15
2017-06-30 271.36 $54.74 4.96
2017-03-31 273.42 $54.06 5.06
2016-12-31 261.39 $56.18 4.65
2016-09-30 288.53 $55.68 5.18
2016-06-30 222.89 $52.04 4.28
2016-03-31 239.95 $47.15 5.09
2015-12-31 282.37 $42.89 6.58
2015-09-30 268.35 $47.41 5.66
2015-06-30 372.33 $53.46 6.96
2015-03-31 389.19 $49.61 7.85
2014-12-31 312.88 $46.10 6.79
2014-09-30 304.92 $44.17 6.90
2014-06-30 290.63 $40.51 7.18
2014-03-31 281.93 $38.54 7.32
2013-12-31 257.69 $36.48 7.06
2013-09-30 221.92 $34.40 6.45
2013-06-30 198.36 $33.25 5.97
2013-03-31 177.54 $30.92 5.74
2012-12-31 134.91 $29.44 4.58
2012-09-30 137.53 $28.16 4.88
2012-06-30 133.08 $26.53 5.02
2012-03-31 116.14 $26.33 4.41
2011-12-31 101.44 $26.55 3.82
2011-09-30 85.86 $25.66 3.35
2011-06-30 98.55 $24.97 3.95
2011-03-31 67.72 $23.48 2.88
2010-12-31 61.80 $22.66 2.73
2010-09-30 51.73 $21.28 2.43
2010-06-30 43.74 $21.54 2.03
2010-03-31 52.90 $22.29 2.37
2009-12-31 49.31 $21.71 2.27
2009-09-30 46.57 $22.81 2.04
2009-06-30 41.62 $21.62 1.92
2009-03-31 48.32 $20.86 2.32
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $30.847B $10.982B
Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00